J&J makes new in­vest­ments in mi­cro­bio­me R&D; UK’s Ar­ix out to raise £100 mil­lion for new biotech in­vest­ments

• J&J is mak­ing some new in­vest­ments in mi­cro­bio­me re­search, in­clud­ing adding Caelus Health to its J&J In­no­va­tion port­fo­lio. “These col­lab­o­ra­tions and in­vest­ments will cre­ate crit­i­cal new in­sights to ad­dress meta­bol­ic dis­or­ders through mi­cro­bio­me-based di­ag­nos­tics and ther­a­peu­tics,” said Dirk Gev­ers, PhD, Glob­al Head, Janssen Hu­man Mi­cro­bio­me In­sti­tute. “By part­ner­ing with en­tre­pre­neurs, biotechs and aca­d­e­mics and bring­ing in­no­v­a­tive op­por­tu­ni­ties to­geth­er with our ex­per­tise, we look to move mi­cro­bio­me sci­ence for­ward and de­liv­er fu­ture so­lu­tions that pro­mote in­di­vid­ual health.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.